Dr. Paul Feldman, PhD

Chief Scientific Officer at Aktis Oncology

Speaker

Paul received his PhD from the University of CA, Berkeley and then joined Glaxo Inc.. At GlaxoSmithKline Paul rose to senior vice president and was part of discovering five approved drugs. In 2015 Paul co-founded and was CEO of Phoundry Pharmaceuticals, a metabolic diseases peptide therapeutics company. Phoundry was acquired by Intarcia Therapeutics and Paul was Head of Discovery and Translational Medicine. His team discovered several peptide assets for treatment of metabolic diseases. In 2020 Paul became Chief Scientific Officer of Aktis Oncology. Aktis is focused on discovering and developing tumor specific binding miniprotein radioconjugates to treat solid-tumor cancers.